drug development

Pharma

Product sales, mergers and layoffs may be in the cards at Adamis

With studies of its lone clinical asset on the rocks, Adamis is weighing its future. And as it stands, all options are on the table.
Fraiser Kansteiner Oct 4, 2022 9:40am

Allele's infringement suit against Regeneron will proceed

Mar 3, 2022 1:23pm

Lilly, Novartis executives commend Pfizer on Paxlovid

Jan 20, 2022 8:00am

Biogen posts more Aduhelm data

Nov 11, 2021 5:15pm

Ardelyx cuts 65% of staff as FDA gives no clarity on kidney drug

Oct 13, 2021 11:46am

Novartis' rare disease campaign draws on comic book characters

Aug 30, 2021 9:50am